{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:16:19Z","timestamp":1789060579051,"version":"build-2803163510"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40256-025-00724-1","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T13:06:34Z","timestamp":1743858394000},"page":"443-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-9852","authenticated-orcid":false,"given":"Harsh","family":"Goel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Roma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayanika","family":"Sreejith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Nadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"724_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.006363","volume":"13","author":"L Chacko","year":"2020","unstructured":"Chacko L, et al. Effects of percutaneous coronary intervention on death and myocardial infarction stratified by stable and unstable coronary artery disease. Circ Cardiovasc Qual Outcomes. 2020;13: e006363.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"724_CR2","doi-asserted-by":"publisher","first-page":"E126","DOI":"10.5888\/pcd10.120322","volume":"10","author":"JC Will","year":"2013","unstructured":"Will JC, Valderrama AL, Yoon PW. Preventable hospitalizations and emergency department visits for angina, United States, 1995\u20132010. Prev Chronic Dis. 2013;10:E126.","journal-title":"Prev Chronic Dis"},{"key":"724_CR3","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin SS, et al. 2024 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149:e347\u2013913.","journal-title":"Circulation"},{"key":"724_CR4","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1161\/CIRCULATIONAHA.107.720953","volume":"117","author":"H Hemingway","year":"2008","unstructured":"Hemingway H, et al. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation. 2008;117:1526\u201336.","journal-title":"Circulation"},{"key":"724_CR5","first-page":"353","volume":"4","author":"J Kempf","year":"2011","unstructured":"Kempf J, Buysman E, Brixner D. Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting. Am Health Drug Benef. 2011;4:353\u201361.","journal-title":"Am Health Drug Benef"},{"key":"724_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/clc.22628","volume":"40","author":"F Kureshi","year":"2017","unstructured":"Kureshi F, et al. The prevalence and management of angina among patients with chronic coronary artery disease across US outpatient cardiology practices: insights from the Angina Prevalence and Provider Evaluation of Angina Relief (APPEAR) study. Clin Cardiol. 2017;40:6\u201310.","journal-title":"Clin Cardiol"},{"key":"724_CR7","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1001\/archinternmed.2009.295","volume":"169","author":"JF Beltrame","year":"2009","unstructured":"Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study. Arch Intern Med. 2009;169:1491\u20139.","journal-title":"Arch Intern Med"},{"key":"724_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/CIRCULATIONAHA.120.048194","volume":"142","author":"S Bangalore","year":"2020","unstructured":"Bangalore S, Maron DJ, Stone GW, Hochman JS. Routine revascularization versus initial medical therapy for stable ischemic heart disease: a systematic review and meta-analysis of randomized trials. Circulation. 2020;142:841\u201357.","journal-title":"Circulation"},{"key":"724_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","volume":"382","author":"DJ Maron","year":"2020","unstructured":"Maron DJ, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382:1395\u2013407.","journal-title":"N Engl J Med"},{"key":"724_CR10","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503\u201316.","journal-title":"N Engl J Med"},{"key":"724_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/2047487318800511","volume":"26","author":"SU Khan","year":"2019","unstructured":"Khan SU, et al. Meta-analysis of long-term outcomes of percutaneous coronary intervention versus medical therapy in stable coronary artery disease. Eur J Prev Cardiol. 2019;26:433\u20136.","journal-title":"Eur J Prev Cardiol"},{"key":"724_CR12","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa1505532","volume":"373","author":"SP Sedlis","year":"2015","unstructured":"Sedlis SP, et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med. 2015;373:1937\u201346.","journal-title":"N Engl J Med"},{"key":"724_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa072771","volume":"359","author":"WS Weintraub","year":"2008","unstructured":"Weintraub WS, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677\u201387.","journal-title":"N Engl J Med"},{"key":"724_CR14","first-page":"137","volume":"117","author":"HR Figulla","year":"2020","unstructured":"Figulla HR, et al. Percutaneous coronary intervention in stable coronary heart disease\u2014is less more? Dtsch Arztebl Int. 2020;117:137\u201344.","journal-title":"Dtsch Arztebl Int"},{"key":"724_CR15","doi-asserted-by":"crossref","unstructured":"Byty\u00e7i I, Morina D, Bytyqi S, Bajraktari G, Henein MY. Percutaneous coronary intervention is not superior to optimal medical therapy in chronic coronary syndrome: a meta-analysis. J Clin Med. 2023;12.","DOI":"10.3390\/jcm12041395"},{"key":"724_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1056\/NEJMoa0907272","volume":"362","author":"MR Patel","year":"2010","unstructured":"Patel MR, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362:886\u201395.","journal-title":"N Engl J Med"},{"key":"724_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jacc.2013.09.055","volume":"63","author":"SM Bradley","year":"2014","unstructured":"Bradley SM, et al. Normal coronary rates for elective angiography in the Veterans Affairs Healthcare System: insights from the VA CART program (veterans affairs clinical assessment reporting and tracking). J Am Coll Cardiol. 2014;63:417\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"724_CR18","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/heartjnl-2023-322345","volume":"109","author":"K Wel\u00e9n Schef","year":"2023","unstructured":"Wel\u00e9n Schef K, et al. Prevalence of angina pectoris and association with coronary atherosclerosis in a general population. Heart. 2023;109:1450\u20139.","journal-title":"Heart"},{"key":"724_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023207","volume":"11","author":"N Mileva","year":"2022","unstructured":"Mileva N, et al. Prevalence of coronary microvascular disease and coronary vasospasm in patients with nonobstructive coronary artery disease: systematic review and meta-analysis. J Am Heart Assoc. 2022;11: e023207.","journal-title":"J Am Heart Assoc"},{"key":"724_CR20","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/archinte.168.12.1310","volume":"168","author":"TM Maddox","year":"2008","unstructured":"Maddox TM, et al. Angina at 1 year after myocardial infarction: prevalence and associated findings. Arch Intern Med. 2008;168:1310\u20136.","journal-title":"Arch Intern Med"},{"key":"724_CR21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1067\/mhj.2002.125505","volume":"144","author":"R Holubkov","year":"2002","unstructured":"Holubkov R, et al. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J. 2002;144:826\u201333.","journal-title":"Am Heart J"},{"key":"724_CR22","first-page":"371","volume":"81","author":"JP Camilleri","year":"1988","unstructured":"Camilleri JP, Joseph D. Effets de la trimetazidine (Vastarel 20 mg) sur l\u2019infarctus experimental du rat perfuse. Arch Mal Coeur Vaiss. 1988;81:371.","journal-title":"Arch Mal Coeur Vaiss"},{"key":"724_CR23","first-page":"124","volume":"7","author":"P Catroux","year":"1986","unstructured":"Catroux P, Dorian C, Harpey C, Cambar J. Mise en evidence de l\u2019effet protecteur de la trimetazidine vis-a-vis de l\u2019enzymurie induite par clampage du pedicule renal chez le rat. Nephrologie. 1986;7:124.","journal-title":"Nephrologie"},{"key":"724_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1527-3466.1988.tb00381.x","volume":"6","author":"C Harpey","year":"1988","unstructured":"Harpey C, Clauser P, Labrid C, Freyria J, Poirier J. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev. 1988;6:292\u2013312.","journal-title":"Cardiovasc Drug Rev"},{"key":"724_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1536\/ihj.18.120","volume":"18","author":"Y Imai","year":"1977","unstructured":"Imai Y, Himori N, Taira N. Cardiohemodynamic effects of SK&F 24260, D 600, diltiazem, dilazep, and trimetazidine in the dog. Jpn Heart J. 1977;18:120\u201331.","journal-title":"Jpn Heart J"},{"key":"724_CR26","first-page":"230","volume":"260","author":"N Toda","year":"1982","unstructured":"Toda N, Usui H, Osumi S, Kanda M, Kitao K. Influence of trimetazidine, an antianginal drug, on isolated dog arteries and veins. Arch Int Pharmacodyn Ther. 1982;260:230\u201343.","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"724_CR27","first-page":"316","volume":"237","author":"T Yanagisawa","year":"1979","unstructured":"Yanagisawa T, Satoh K, Taira N. Simultaneous assessment of the effects of trimetazidine on the myocardium and coronary vasculature of the dog. Arch Int Pharmacodyn Ther. 1979;237:316\u201329.","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"724_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0021-5198(19)36224-9","volume":"21","author":"M Nagata","year":"1971","unstructured":"Nagata M, Imamura I, Fugono R, Sugimoto J. The actions of trimetazidine on isolated guinea-pig atria. Jpn J Pharmacol. 1971;21:337\u201343.","journal-title":"Jpn J Pharmacol"},{"key":"724_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0021-5198(19)67570-0","volume":"17","author":"Y Fujita","year":"1967","unstructured":"Fujita Y. Effects of 1-(2,3,4-trimethoxy benzyl)-piperazine dihydrochloride on the cardiovascular system in the rabbit. Jpn J Pharmacol. 1967;17:19\u201329.","journal-title":"Jpn J Pharmacol"},{"key":"724_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0021-5198(19)52480-5","volume":"33","author":"M Asano","year":"1983","unstructured":"Asano M, Ohkubo C, Sawanobori K. Vasodilator effect of trimetazidine on cutaneous microcirculation of normal conscious rabbits. Jpn J Pharmacol. 1983;33:891\u20133.","journal-title":"Jpn J Pharmacol"},{"issue":"Suppl 4","key":"724_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/BF00051292","volume":"4","author":"S Dalla-Volta","year":"1990","unstructured":"Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc drugs Ther. 1990;4(Suppl 4):853\u20139.","journal-title":"Cardiovasc drugs Ther"},{"key":"724_CR32","doi-asserted-by":"crossref","unstructured":"Detry JM et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol. 1994;37:279\u201388.","DOI":"10.1111\/j.1365-2125.1994.tb04276.x"},{"key":"724_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/FJC.0b013e31817bdd66","volume":"51","author":"R Belardinelli","year":"2008","unstructured":"Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol. 2008;51:611\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"key":"724_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00129784-200505040-00006","volume":"5","author":"T El-Kady","year":"2005","unstructured":"El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs. 2005;5:271\u20138.","journal-title":"Am J Cardiovasc Drugs"},{"key":"724_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/00005344-199301000-00019","volume":"21","author":"J Aussedat","year":"1993","unstructured":"Aussedat J, et al. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol. 1993;21:128\u201335.","journal-title":"J Cardiovasc Pharmacol"},{"key":"724_CR36","doi-asserted-by":"publisher","first-page":"45B","DOI":"10.1016\/S0002-9149(99)80462-7","volume":"76","author":"L Kay","year":"1995","unstructured":"Kay L, Finelli C, Aussedat J, Guarnieri C, Rossi A. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function. Am J Cardiol. 1995;76:45B-49B.","journal-title":"Am J Cardiol"},{"key":"724_CR37","first-page":"97","volume":"286","author":"N Lavanchy","year":"1987","unstructured":"Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther. 1987;286:97\u2013110.","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"724_CR38","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","volume":"86","author":"PF Kantor","year":"2000","unstructured":"Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580\u20138.","journal-title":"Circ Res"},{"key":"724_CR39","doi-asserted-by":"publisher","first-page":"42K","DOI":"10.1016\/S0002-9149(98)00536-0","volume":"82","author":"FV Mody","year":"1998","unstructured":"Mody FV, et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol. 1998;82:42K-49K.","journal-title":"Am J Cardiol"},{"key":"724_CR40","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1161\/01.RES.0000086964.07404.A5","volume":"93","author":"GD Lopaschuk","year":"2003","unstructured":"Lopaschuk GD, Barr R, Thomas PD, Dyck JRB. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2003;93:e33\u20137.","journal-title":"Circ Res"},{"key":"724_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1755-5922.2011.00275.x","volume":"30","author":"M Bucci","year":"2012","unstructured":"Bucci M, et al. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther. 2012;30:333\u201341.","journal-title":"Cardiovasc Ther"},{"key":"724_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.707399","volume":"12","author":"H Shu","year":"2021","unstructured":"Shu H, et al. Trimetazidine attenuates heart failure by improving myocardial metabolism via AMPK. Front Pharmacol. 2021;12: 707399.","journal-title":"Front Pharmacol"},{"key":"724_CR43","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3389\/fphar.2020.01255","volume":"11","author":"H Li","year":"2020","unstructured":"Li H, et al. Trimetazidine ameliorates myocardial metabolic remodeling in isoproterenol-induced rats through regulating ketone body metabolism via activating AMPK and PPAR \u03b1. Front Pharmacol. 2020;11:1255.","journal-title":"Front Pharmacol"},{"key":"724_CR44","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.metabol.2015.10.022","volume":"65","author":"Z Liu","year":"2016","unstructured":"Liu Z, et al. The protective effect of trimetazidine on myocardial ischemia\/reperfusion injury through activating AMPK and ERK signaling pathway. Metabolism. 2016;65:122\u201330.","journal-title":"Metabolism"},{"key":"724_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19:121\u201335.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"724_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.81","volume":"48","author":"S-M Jeon","year":"2016","unstructured":"Jeon S-M. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016;48: e245.","journal-title":"Exp Mol Med"},{"key":"724_CR47","doi-asserted-by":"crossref","unstructured":"Mahfoudh-Boussaid A, Hadj Ayed Tka K, Zaouali MA, Rosell\u00f3-Catafau J, Ben Abdennebi H. Effects of trimetazidine on the Akt\/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion. Ren Fail. 2014;36:1436\u201342.","DOI":"10.3109\/0886022X.2014.949765"},{"key":"724_CR48","first-page":"16991","volume":"8","author":"X Hu","year":"2015","unstructured":"Hu X, et al. Mesenchymal stem cells preconditioned with trimetazidine promote neovascularization of hearts under hypoxia\/reoxygenation injury. Int J Clin Exp Med. 2015;8:16991\u20137005.","journal-title":"Int J Clin Exp Med"},{"key":"724_CR49","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41581-022-00587-8","volume":"18","author":"CT Taylor","year":"2022","unstructured":"Taylor CT, Scholz CC. The effect of HIF on metabolism and immunity. Nat Rev Nephrol. 2022;18:573\u201387.","journal-title":"Nat Rev Nephrol"},{"key":"724_CR50","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1152\/physrev.1992.72.4.881","volume":"72","author":"GJ van der Vusse","year":"1992","unstructured":"van der Vusse GJ, Glatz JF, Stam HC, Reneman RS. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev. 1992;72:881\u2013940.","journal-title":"Physiol Rev"},{"key":"724_CR51","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1172\/JCI112174","volume":"76","author":"JA Wisneski","year":"1985","unstructured":"Wisneski JA, et al. Metabolic fate of extracted glucose in normal human myocardium. J Clin Investig. 1985;76:1819\u201327.","journal-title":"J Clin Investig"},{"key":"724_CR52","doi-asserted-by":"crossref","unstructured":"Gandoy-Fieiras N, Gonzalez-Juanatey JR, Eiras S. Myocardium metabolism in physiological and pathophysiological states: implications of epicardial adipose tissue and potential therapeutic targets. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21072641"},{"key":"724_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0008-6363(96)00245-3","volume":"33","author":"WC Stanley","year":"1997","unstructured":"Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 1997;33:243\u201357.","journal-title":"Cardiovasc Res"},{"key":"724_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejphar.2004.09.003","volume":"503","author":"P Monteiro","year":"2004","unstructured":"Monteiro P, Duarte AI, Gon\u00e7alves LM, Moreno A, Provid\u00eancia LA. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia. Eur J Pharmacol. 2004;503:123\u20138.","journal-title":"Eur J Pharmacol"},{"key":"724_CR55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00395-004-0505-4","volume":"100","author":"C Pantos","year":"2005","unstructured":"Pantos C, et al. Trimetazidine protects isolated rat hearts against ischemia-reperfusion injury in an experimental timing-dependent manner. Basic Res Cardiol. 2005;100:154\u201360.","journal-title":"Basic Res Cardiol"},{"key":"724_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.niox.2006.09.001","volume":"16","author":"P Di Napoli","year":"2007","unstructured":"Di Napoli P, et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide Biol Chem. 2007;16:228\u201336.","journal-title":"Nitric Oxide Biol Chem"},{"key":"724_CR57","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1124\/jpet.109.165175","volume":"333","author":"M Khan","year":"2010","unstructured":"Khan M, et al. Trimetazidine, administered at the onset of reperfusion, ameliorates myocardial dysfunction and injury by activation of p38 mitogen-activated protein kinase and Akt signaling. J Pharmacol Exp Ther. 2010;333:421\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"724_CR58","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00109-018-1664-3","volume":"96","author":"S Wu","year":"2018","unstructured":"Wu S, et al. Trimetazidine protects against myocardial ischemia\/reperfusion injury by inhibiting excessive autophagy. J Mol Med (Berl). 2018;96:791\u2013806.","journal-title":"J Mol Med (Berl)"},{"key":"724_CR59","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000369246","volume":"130","author":"Y-C Liu","year":"2015","unstructured":"Liu Y-C, Li L, Su Q, Liu T, Tang Z. Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function in a Swine model of coronary microembolization. Cardiology. 2015;130:130\u20136.","journal-title":"Cardiology"},{"key":"724_CR60","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jphs.2019.01.016","volume":"139","author":"S-G Tang","year":"2019","unstructured":"Tang S-G, et al. Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2\/TRPC3-induced oxidative stress. J Pharmacol Sci. 2019;139:311\u20138.","journal-title":"J Pharmacol Sci"},{"key":"724_CR61","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejphar.2013.03.027","volume":"707","author":"Q Wu","year":"2013","unstructured":"Wu Q, et al. Mechanisms underlying protective effects of trimetazidine on endothelial progenitor cells biological functions against H2O2-induced injury: involvement of antioxidation and Akt\/eNOS signaling pathways. Eur J Pharmacol. 2013;707:87\u201394.","journal-title":"Eur J Pharmacol"},{"key":"724_CR62","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1177\/0091270011422813","volume":"52","author":"L Ozbay","year":"2012","unstructured":"Ozbay L, Unal DO, Erol D. Food effect on bioavailability of modified-release trimetazidine tablets. J Clin Pharmacol. 2012;52:1535\u20139.","journal-title":"J Clin Pharmacol"},{"key":"724_CR63","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1055\/a-1180-4357","volume":"70","author":"T K\u00f6rnicke","year":"2020","unstructured":"K\u00f6rnicke T, et al. Single ascending dose study to assess pharmacokinetic linearity, safety, and tolerability of trimetazidine-modified release in healthy human subjects. Drug Res (Stuttg). 2020;70:472\u20137.","journal-title":"Drug Res. (Stuttg)"},{"key":"724_CR64","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/00498259609046702","volume":"26","author":"PJ Jackson","year":"1996","unstructured":"Jackson PJ, et al. Identification of trimetazidine metabolites in human urine and plasma. Xenobiotica. 1996;26:221\u20138.","journal-title":"Xenobiotica"},{"key":"724_CR65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF03190575","volume":"29","author":"P G\u00e9nissel","year":"2004","unstructured":"G\u00e9nissel P, Chodjania Y, Demolis JL, Ragueneau I, Jaillon P. Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. Eur J Drug Metab Pharmacokinet. 2004;29:61\u20138.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"724_CR66","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bdd.350","volume":"24","author":"J Barr\u00e9","year":"2003","unstructured":"Barr\u00e9 J, et al. Pharmacokinetic profile of a modified release formulation of trimetazidine (TMZ MR 35 mg) in the elderly and patients with renal failure. Biopharm Drug Dispos. 2003;24:159\u201364.","journal-title":"Biopharm Drug Dispos"},{"key":"724_CR67","unstructured":"EMA. European Medicines Agency Assessment Report for trimetazidine containing medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/trimetazidine-article-31-referral-assessment-report_en.pdf."},{"key":"724_CR68","doi-asserted-by":"crossref","unstructured":"Kim S, et al. Trimetazidine use and the risk of parkinsonism: a nationwide population-based study. Int J Environ Res Public Health. 2020;17.","DOI":"10.3390\/ijerph17197256"},{"key":"724_CR69","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0140-6736(20)31790-6","volume":"396","author":"R Ferrari","year":"2020","unstructured":"Ferrari R, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2020;396:830\u20138.","journal-title":"Lancet (London, England)"},{"key":"724_CR70","first-page":"1331","volume":"79","author":"P Sellier","year":"1986","unstructured":"Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study. Arch Mal Coeur Vaiss. 1986;79:1331\u20136.","journal-title":"Arch Mal Coeur Vaiss"},{"issue":"Suppl 4","key":"724_CR71","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/BF00051287","volume":"4","author":"C Monp\u00e8re","year":"1990","unstructured":"Monp\u00e8re C, Brochier M, Demange J, Ducloux G, Warin JF. Combination of trimetazidine with nifedipine in effort angina. Cardiovasc Drugs Ther. 1990;4(Suppl 4):824\u20135.","journal-title":"Cardiovasc Drugs Ther"},{"key":"724_CR72","first-page":"1779","volume":"15","author":"M Gallet","year":"1986","unstructured":"Gallet M. Clinical effectiveness of trimetazidine in stable effort angina. A double-blind versus placebo controlled study. Presse Med. 1986;15:1779\u201382.","journal-title":"Presse Med"},{"key":"724_CR73","first-page":"1775","volume":"15","author":"J Passeron","year":"1986","unstructured":"Passeron J. Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency. A double-blind versus placebo study. Presse Med. 1986;15:1775\u20138.","journal-title":"Presse Med"},{"key":"724_CR74","doi-asserted-by":"publisher","first-page":"644","DOI":"10.2143\/AC.59.6.2005248","volume":"59","author":"N Koylan","year":"2004","unstructured":"Koylan N, et al. Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS). Acta Cardiol. 2004;59:644\u201350.","journal-title":"Acta Cardiol"},{"key":"724_CR75","doi-asserted-by":"publisher","first-page":"P3149","DOI":"10.1093\/eurheartj\/eht309.P3149","volume":"34","author":"E Nesukay","year":"2013","unstructured":"Nesukay E. Assessment of antianginal combination in the treatment of patients with stable angina pectoris. Eur Heart J. 2013;34:P3149\u2013P3149.","journal-title":"Eur Heart J"},{"key":"724_CR76","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2165\/00129784-200505050-00005","volume":"5","author":"R Gupta","year":"2005","unstructured":"Gupta R, Sawhney JPS, Narain VS. Treatment of stable angina pectoris with trimetazidine modified release in indian primary-care practice. Am J Cardiovasc Drugs. 2005;5:325\u20139.","journal-title":"Am J Cardiovasc Drugs"},{"key":"724_CR77","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00019501-200304000-00010","volume":"14","author":"M Marzilli","year":"2003","unstructured":"Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis. 2003;14:171\u20139.","journal-title":"Coron Artery Dis"},{"key":"724_CR78","doi-asserted-by":"publisher","unstructured":"Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. In: Cochrane database of systematic reviews. Ciapponi A, editor. Wiley; 2005. https:\/\/doi.org\/10.1002\/14651858.CD003614.pub2.","DOI":"10.1002\/14651858.CD003614.pub2"},{"key":"724_CR79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000332369","volume":"120","author":"N Danchin","year":"2011","unstructured":"Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology. 2011;120:59\u201372.","journal-title":"Cardiology"},{"key":"724_CR80","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ijcard.2014.10.149","volume":"177","author":"S Peng","year":"2014","unstructured":"Peng S, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 2014;177:780\u20135.","journal-title":"Int J Cardiol"},{"key":"724_CR81","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2217\/cer-2017-0011","volume":"6","author":"Z Meiszterics","year":"2017","unstructured":"Meiszterics Z, K\u00f3nyi A, Hild G, S\u00e1rszegi Z, Gaszner B. Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes. J Comp Eff Res. 2017;6:649\u201357.","journal-title":"J Comp Eff Res"},{"key":"724_CR82","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/hrt.78.4.353","volume":"78","author":"SC Manchanda","year":"1997","unstructured":"Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart. 1997;78:353\u20137.","journal-title":"Heart"},{"key":"724_CR83","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40119-021-00249-z","volume":"11","author":"Y Lopatin","year":"2022","unstructured":"Lopatin Y, Petrova P. Effectiveness and tolerability of trimetazidine 80 mg once daily in patients with stable angina uncontrolled with bisoprolol-based therapy: the modus vivendi observational study. Cardiol Ther. 2022;11:93\u2013111.","journal-title":"Cardiol Ther."},{"key":"724_CR84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00045391-200501000-00006","volume":"12","author":"EI Chazov","year":"2005","unstructured":"Chazov EI, et al. Trimetazidine in angina combination therapy-the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther. 2005;12:35\u201342.","journal-title":"Am J Ther"},{"key":"724_CR85","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1742-1241.2003.tb10632.x","volume":"57","author":"F K\u00f6lbel","year":"2003","unstructured":"K\u00f6lbel F, Bada V. Trimetazidine in geriatric patients with stable angina pectoris: the tiger study. Int J Clin Pract. 2003;57:867\u201370.","journal-title":"Int J Clin Pract"},{"key":"724_CR86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/BF01616842","volume":"8","author":"S Nalbantgil","year":"1999","unstructured":"Nalbantgil S, Altintigbreve A, Yilmaz H, Nalbantgil I, \u00d6nder R. The effect of trimetazidine in the treatment of microvascular angina. Int J Angiol. 1999;8:40\u20133.","journal-title":"Int J Angiol"},{"key":"724_CR87","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00019501-200003000-00012","volume":"11","author":"D Rogacka","year":"2000","unstructured":"Rogacka D, et al. Effects of trimetazidine on clinical symptoms and tolerance of exercise of patients with syndrome X: a preliminary study. Coron Artery Dis. 2000;11:171\u20137.","journal-title":"Coron Artery Dis"},{"key":"724_CR88","doi-asserted-by":"crossref","unstructured":"Leonova IA, Boldueva S, Zakharova O, Gaykovaya L. P887Trimetazidine improves symptoms and reduces microvascular dysfunction in patients with microvascular angina. Eur Heart J. 2017;38.","DOI":"10.1093\/eurheartj\/ehx501.P887"},{"key":"724_CR89","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40256-017-0254-z","volume":"18","author":"YH Kim","year":"2018","unstructured":"Kim YH, et al. Impact of trimetazidine treatment on 5-year clinical outcomes in patients with significant coronary artery spasm: a propensity score matching study. Am J Cardiovasc Drugs. 2018;18:117\u201327.","journal-title":"Am J Cardiovasc Drugs"},{"key":"724_CR90","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1097\/MJT.0000000000001430","volume":"28","author":"E Bobescu","year":"2021","unstructured":"Bobescu E, et al. Trimetazidine therapy in coronary artery disease: the impact on oxidative stress, inflammation, endothelial dysfunction, and long-term prognosis. Am J Ther. 2021;28:e540\u20137.","journal-title":"Am J Ther"},{"key":"724_CR91","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0140-6736(20)31790-6","volume":"396","author":"R Ferrari","year":"2020","unstructured":"Ferrari R, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;396:830\u20138.","journal-title":"Lancet"},{"key":"724_CR92","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/0003319720987745","volume":"72","author":"C Wang","year":"2021","unstructured":"Wang C, Chen W, Yu M, Yang P. Efficacy of trimetazidine in limiting periprocedural myocardial injury in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Angiology. 2021;72:511\u201323.","journal-title":"Angiology"},{"key":"724_CR93","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/FJC.0000000000001453","volume":"82","author":"S Park","year":"2023","unstructured":"Park S, et al. Impact of trimetazidine on the incident heart failure after coronary artery revascularization. J Cardiovasc Pharmacol. 2023;82:318\u201326.","journal-title":"J Cardiovasc Pharmacol"},{"key":"724_CR94","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1053\/euhj.1999.2071","volume":"21","author":"M Heras","year":"2000","unstructured":"Heras M. Atherosclerosis: a systemic condition that requires a global approach. Eur Heart J. 2000;21:872\u20133.","journal-title":"Eur Heart J"},{"key":"724_CR95","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000375289","volume":"131","author":"N Zhang","year":"2015","unstructured":"Zhang N, et al. The effectiveness of preoperative trimetazidine on myocardial preservation in coronary artery bypass graft patients: a systematic review and meta-analysis. Cardiology. 2015;131:86\u201396.","journal-title":"Cardiology"},{"key":"724_CR96","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12872-021-02287-w","volume":"21","author":"Z-L Dai","year":"2021","unstructured":"Dai Z-L, et al. Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial. BMC Cardiovasc Disord. 2021;21:473.","journal-title":"BMC Cardiovasc Disord"},{"key":"724_CR97","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJMra063052","volume":"356","author":"S Neubauer","year":"2007","unstructured":"Neubauer S. The failing heart\u2013an engine out of fuel. N Engl J Med. 2007;356:1140\u201351.","journal-title":"N Engl J Med"},{"key":"724_CR98","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","volume":"14","author":"DA Brown","year":"2017","unstructured":"Brown DA, et al. Mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2017;14:238\u201350.","journal-title":"Nat Rev Cardiol"},{"key":"724_CR99","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ihj.2016.03.021","volume":"68","author":"A Momen","year":"2016","unstructured":"Momen A, et al. Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy\u2014six months follow-up result. Indian Heart J. 2016;68:809\u201315.","journal-title":"Indian Heart J"},{"key":"724_CR100","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3892\/etm.2016.3363","volume":"12","author":"H Li","year":"2016","unstructured":"Li H, Liu F-Y, Li X-L, Li X-M, Zhu L. Clinical effects of carvedilol and trimetazidine for the treatmentof alcoholic myocardiopathy. Exp Ther Med. 2016;12:979\u201382.","journal-title":"Exp Ther Med"},{"key":"724_CR101","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ihj.2016.04.023","volume":"68","author":"S Jatain","year":"2016","unstructured":"Jatain S, et al. Metabolic manipulation in dilated cardiomyopathy: assessing the role of trimetazidine. Indian Heart J. 2016;68:803\u20138.","journal-title":"Indian Heart J"},{"key":"724_CR102","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/hrt.2011.226332","volume":"97","author":"G Fragasso","year":"2011","unstructured":"Fragasso G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart. 2011;97:1495\u2013500.","journal-title":"Heart"},{"key":"724_CR103","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00380-008-1118-x","volume":"24","author":"Y Gunes","year":"2009","unstructured":"Gunes Y, Guntekin U, Tuncer M, Sahin M. Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels. 2009;24:277\u201382.","journal-title":"Heart Vessels"},{"key":"724_CR104","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.ehj.2004.06.034","volume":"25","author":"C Vitale","year":"2004","unstructured":"Vitale C, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25:1814\u201321.","journal-title":"Eur Heart J"},{"key":"724_CR105","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00129784-200505040-00006","volume":"5","author":"T El-Kady","year":"2005","unstructured":"El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy. Am J Cardiovasc Drugs. 2005;5:271\u20138.","journal-title":"Am J Cardiovasc Drugs"},{"key":"724_CR106","doi-asserted-by":"crossref","unstructured":"Di Napoli P, Giovanni PD, Gaeta MA, Taccardi AA, Barsotti A. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini D\u2019Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol. 2007;50:585\u20139.","DOI":"10.1097\/FJC.0b013e31814fa9cb"},{"key":"724_CR107","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijcard.2012.09.123","volume":"163","author":"G Fragasso","year":"2013","unstructured":"Fragasso G, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol. 2013;163:320\u20135.","journal-title":"Int J Cardiol"},{"key":"724_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2023-002579","volume":"11","author":"S Nassiri","year":"2024","unstructured":"Nassiri S, et al. Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis. Open Heart. 2024;11: e002579.","journal-title":"Open Heart."},{"key":"724_CR109","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jvs.2022.12.015","volume":"77","author":"MA Eid","year":"2023","unstructured":"Eid MA, et al. The global burden of peripheral artery disease. J Vasc Surg. 2023;77:1119-1126.e1.","journal-title":"J Vasc Surg"},{"key":"724_CR110","doi-asserted-by":"crossref","unstructured":"Gornik HL, et al. ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149.","DOI":"10.1161\/CIR.0000000000001251"},{"key":"724_CR111","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/07853890.2021.1925147","volume":"53","author":"Y Yang","year":"2021","unstructured":"Yang Y, Xu Q, Li T, Shao S. Trimetazidine ameliorates hindlimb ischaemic damage in type 2 diabetic mice. Ann Med. 2021;53:1099\u2013107.","journal-title":"Ann Med"},{"key":"724_CR112","doi-asserted-by":"publisher","first-page":"1436072","DOI":"10.3389\/fphar.2024.1436072","volume":"15","author":"Y Pan","year":"2024","unstructured":"Pan Y, et al. Trimetazidine improves angiogenesis and tissue perfusion in ischemic rat skeletal muscle. Front Pharmacol. 2024;15:1436072.","journal-title":"Front Pharmacol"},{"key":"724_CR113","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.phrs.2011.01.003","volume":"63","author":"C Vitale","year":"2011","unstructured":"Vitale C, et al. Trimetazidine improves exercise performance in patients with peripheral arterial disease. Pharmacol Res. 2011;63:278\u201383.","journal-title":"Pharmacol Res"},{"key":"724_CR114","first-page":"188","volume":"20","author":"Y-S Chu","year":"2016","unstructured":"Chu Y-S, Li D-X, Zhang M, Jiang T-M. Trimetazidine hydrochloride as a new treatment for patients with peripheral vascular disease\u2013an exploratory trial. Eur Rev Med Pharmacol Sci. 2016;20:188\u201393.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"724_CR115","first-page":"4427","volume":"17","author":"M Hu","year":"2019","unstructured":"Hu M, Wang D, He T. Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity. Exp Ther Med. 2019;17:4427\u201334.","journal-title":"Exp Ther Med"},{"key":"724_CR116","doi-asserted-by":"crossref","unstructured":"Wu M-Y, et al. The incidence of contrast-induced nephropathy and the need of dialysis in patients receiving angiography: a systematic review and meta-analysis. Front Med. 2022;9.","DOI":"10.3389\/fmed.2022.862534"},{"key":"724_CR117","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1038\/sj.ki.5000368","volume":"69","author":"R Mehran","year":"2006","unstructured":"Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int. 2006;69:S11\u20135.","journal-title":"Kidney Int"},{"key":"724_CR118","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s00270-005-0196-8","volume":"28","author":"P Parfrey","year":"2005","unstructured":"Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Interv Radiol. 2005;28:S3\u201311.","journal-title":"Cardiovasc Interv Radiol"},{"key":"724_CR119","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1161\/01.CIR.0000016043.87291.33","volume":"105","author":"CS Rihal","year":"2002","unstructured":"Rihal CS, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259\u201364.","journal-title":"Circulation"},{"key":"724_CR120","doi-asserted-by":"publisher","first-page":"16896","DOI":"10.1038\/s41598-019-53040-5","volume":"9","author":"W Ribitsch","year":"2019","unstructured":"Ribitsch W, Horina JH, Quehenberger F, Rosenkranz AR, Schilcher G. Contrast induced acute kidney injury and its impact on mid-term kidney function, cardiovascular events and mortality. Sci Rep. 2019;9:16896.","journal-title":"Sci Rep"},{"key":"724_CR121","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/CIRCINTERVENTIONS.112.974493","volume":"6","author":"MT James","year":"2013","unstructured":"James MT, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography. Circ Cardiovasc Interv. 2013;6:37\u201343.","journal-title":"Circ Cardiovasc Interv"},{"key":"724_CR122","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.amjcard.2004.03.008","volume":"93","author":"BA Bartholomew","year":"2004","unstructured":"Bartholomew BA, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515\u20139.","journal-title":"Am J Cardiol"},{"key":"724_CR123","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s13244-013-0291-3","volume":"4","author":"RWF Geenen","year":"2013","unstructured":"Geenen RWF, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging. 2013;4:811\u201320.","journal-title":"Insights Imaging"},{"key":"724_CR124","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jvs.2007.10.036","volume":"47","author":"J Cau","year":"2008","unstructured":"Cau J, et al. Trimetazidine reduces early and long-term effects of experimental renal warm ischemia: a dose effect study. J Vasc Surg. 2008;47:852-860.e4.","journal-title":"J Vasc Surg"},{"key":"724_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1072805","volume":"2018","author":"JH Park","year":"2018","unstructured":"Park JH, et al. Effects of post ischemia-reperfusion treatment with trimetazidine on renal injury in rats: insights on delayed renal fibrosis progression. Oxid Med Cell Longev. 2018;2018:1\u201310.","journal-title":"Oxid Med Cell Longev"},{"key":"724_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174624","volume":"913","author":"K Gupta","year":"2021","unstructured":"Gupta K, Pandey S, Bagang N, Mehra K, Singh G. Trimetazidine an emerging paradigm in renal therapeutics: preclinical and clinical insights. Eur J Pharmacol. 2021;913: 174624.","journal-title":"Eur J Pharmacol"},{"key":"724_CR127","doi-asserted-by":"publisher","first-page":"451","DOI":"10.37616\/2212-5043.1146","volume":"32","author":"H Galal","year":"2020","unstructured":"Galal H, Shehta M, Attia S, Bastawy I. Comparing trimetazidine with allopurinol in prevention of contrast induced nephropathy after coronary angiography. J Saudi Heart Assoc. 2020;32:451\u20135.","journal-title":"J Saudi Heart Assoc"},{"key":"724_CR128","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s11255-019-02308-w","volume":"51","author":"X Lian","year":"2019","unstructured":"Lian X, et al. The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization. Int Urol Nephrol. 2019;51:2267\u201372.","journal-title":"Int Urol Nephrol"},{"key":"724_CR129","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/0267659120952057","volume":"36","author":"X Zhang","year":"2021","unstructured":"Zhang X, et al. Preventive effect of trimetazidine on contrast-induced nephropathy undergoing percutaneous coronary intervention in elderly moderate and high risk diabetics stratified by mehran score. Perfusion. 2021;36:491\u2013500.","journal-title":"Perfusion"},{"key":"724_CR130","doi-asserted-by":"crossref","unstructured":"Heshmatzadeh Behzadi A, et al. Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty. Medicine (Baltimore). 2021;100:e24603.","DOI":"10.1097\/MD.0000000000024603"},{"key":"724_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168726","volume":"12","author":"EP Navarese","year":"2017","unstructured":"Navarese EP, et al. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS ONE. 2017;12: e0168726.","journal-title":"PLoS ONE"},{"key":"724_CR132","doi-asserted-by":"crossref","unstructured":"Ye Z, et al. Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency. Medicine (Baltimore). 2017;96:e6059.","DOI":"10.1097\/MD.0000000000006059"},{"key":"724_CR133","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ijcard.2012.11.001","volume":"168","author":"C Vitale","year":"2013","unstructured":"Vitale C, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina\u2014the VASCO-angina study. Int J Cardiol. 2013;168:1078\u201381.","journal-title":"Int J Cardiol"},{"key":"724_CR134","first-page":"344","volume":"15","author":"Z Grabczewska","year":"2008","unstructured":"Grabczewska Z, et al. The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease. Cardiol J. 2008;15:344\u201350.","journal-title":"Cardiol J"},{"issue":"78","key":"724_CR135","first-page":"e1","volume":"154","author":"LW Ribeiro","year":"2007","unstructured":"Ribeiro LW, Ribeiro JP, Stein R, Leit\u00e3o C, Polanczyk CA. Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: a randomized crossover trial. Am Heart J. 2007;154(78):e1-78.e7.","journal-title":"Am Heart J"},{"key":"724_CR136","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2165\/00129784-200303050-00007","volume":"3","author":"P Sellier","year":"2003","unstructured":"Sellier P, Broustet J-P. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35mg in patients with stable angina pectoris. Am J Cardiovasc Drugs. 2003;3:361\u20139.","journal-title":"Am J Cardiovasc Drugs"},{"key":"724_CR137","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1053\/euhj.2001.2896","volume":"22","author":"H Szwed","year":"2001","unstructured":"Szwed H. Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J. 2001;22:2267\u201374.","journal-title":"Eur Heart J"},{"key":"724_CR138","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1023\/A:1007744109064","volume":"13","author":"H Szwed","year":"1999","unstructured":"Szwed H, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther. 1999;13:217\u201322.","journal-title":"Cardiovasc Drugs Ther"},{"key":"724_CR139","doi-asserted-by":"publisher","first-page":"12B","DOI":"10.1016\/S0002-9149(99)80456-1","volume":"76","author":"S Levy","year":"1995","unstructured":"Levy S. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators. Am J Cardiol. 1995;76:12B-16B.","journal-title":"Am J Cardiol"},{"key":"724_CR140","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1556\/650.2021.32138","volume":"162","author":"J Tomcs\u00e1nyi","year":"2021","unstructured":"Tomcs\u00e1nyi J. A trimetazidin hat\u00e1soss\u00e1g\u00e1nak \u00f6sszehasonl\u00edt\u00e1sa a revaszkulariz\u00e1lt \u00e9s a nem revaszkulariz\u00e1lt stabil angin\u00e1s betegeken a ONECAPS-vizsg\u00e1lat alapj\u00e1n. Orv Hetil. 2021;162:1167\u201371.","journal-title":"Orv Hetil"},{"key":"724_CR141","doi-asserted-by":"publisher","first-page":"65","DOI":"10.18087\/cardio.2021.11.n1801","volume":"61","author":"MG Bubnova","year":"2021","unstructured":"Bubnova MG, Aronov DM. Efficacy of trimetazidine\u2014an inhibitor of free fatty acids oxidation in the treatment of patients with stable angina pectoris and heart failure. Kardiologiia. 2021;61:65\u201376.","journal-title":"Kardiologiia"},{"key":"724_CR142","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40119-020-00174-7","volume":"9","author":"MG Glezer","year":"2020","unstructured":"Glezer MG, Vygodin VA. Effectiveness of trimetazidine in patients with stable angina pectoris of various durations: results from ODA. Cardiol Ther. 2020;9:395\u2013408.","journal-title":"Cardiol. Ther."},{"key":"724_CR143","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s12325-018-0674-4","volume":"35","author":"M Glezer","year":"2018","unstructured":"Glezer M. The effectiveness of trimetazidine treatment in patients with stable angina pectoris of various durations: results from the CHOICE-2 Study. Adv Ther. 2018;35:1103\u201313.","journal-title":"Adv Ther"},{"key":"724_CR144","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez Padial L, Maicas Bellido C, Vel\u00e1zquez Mart\u00edn M, Gil Polo B. Estudio prospectivo en pacientes diab\u00e9ticos de la efectividad y la tolerabilidad de la trimetazidina en asociaci\u00f3n al tratamiento previo de su enfermedad coronaria. Estudio DIETRIC. Rev. Cl\u00ednica Espa\u00f1ola. 2005;205:57\u201362.","DOI":"10.1157\/13072496"},{"key":"724_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/4230948","volume":"2019","author":"S Shao","year":"2019","unstructured":"Shao S, et al. Effects of trimetazidine pretreatment on endothelial dysfunction and myocardial injury in unstable angina patients undergoing percutaneous coronary intervention. Cardiol Res Pract. 2019;2019:1\u20137.","journal-title":"Cardiol Res Pract"},{"key":"724_CR146","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.1016\/j.ihj.2018.10.415","volume":"70","author":"DH Kazmi","year":"2018","unstructured":"Kazmi DH, et al. Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention\u2013induced myocardial injury. Indian Heart J. 2018;70:S365\u201371.","journal-title":"Indian Heart J"},{"key":"724_CR147","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.ajem.2017.05.024","volume":"35","author":"R Li","year":"2017","unstructured":"Li R, et al. The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI. Am J Emerg Med. 2017;35:1657\u201361.","journal-title":"Am J Emerg Med"},{"key":"724_CR148","first-page":"58","volume":"5","author":"M Shehata","year":"2014","unstructured":"Shehata M. Cardioprotective effects of oral trimetazidine in diabetic patients with anterior wall myocardial infarction treated with thrombolysis. Cardiol Res. 2014;5:58\u201367.","journal-title":"Cardiol Res"},{"key":"724_CR149","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.amjcard.2014.04.052","volume":"114","author":"M Shehata","year":"2014","unstructured":"Shehata M. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention. Am J Cardiol. 2014;114:389\u201394.","journal-title":"Am J Cardiol"},{"key":"724_CR150","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ijcard.2014.04.168","volume":"174","author":"J Chen","year":"2014","unstructured":"Chen J, et al. Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: a 1-year prospective follow-up study. Int J Cardiol. 2014;174:634\u20139.","journal-title":"Int J Cardiol"},{"key":"724_CR151","first-page":"545","volume":"29","author":"X Lin","year":"2013","unstructured":"Lin X, et al. Cardioprotective effects of atorvastatin plus trimetazidine in percutaneous coronary intervention, Pakistan. J Med Sci. 2013;29:545\u20138.","journal-title":"J Med Sci"},{"key":"724_CR152","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4070\/kcj.2013.43.7.462","volume":"43","author":"S Demirelli","year":"2013","unstructured":"Demirelli S, et al. The impact of trimetazidine treatment on left ventricular functions and plasma brain natriuretic peptide levels in patients with non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention. Korean Circ J. 2013;43:462\u20137.","journal-title":"Korean Circ J."},{"key":"724_CR153","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1185\/030079902125001146","volume":"18","author":"L Polonski","year":"2002","unstructured":"Polonski L, Dec I, Wojnar R, Wilczek K. Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. Curr Med Res Opin. 2002;18:389\u201396.","journal-title":"Curr Med Res Opin"},{"key":"724_CR154","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00129784-200707020-00006","volume":"7","author":"A Labrou","year":"2007","unstructured":"Labrou A, et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs. 2007;7:143\u201350.","journal-title":"Am J Cardiovasc Drugs"},{"key":"724_CR155","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/hrt.2006.107524","volume":"93","author":"L Bonello","year":"2007","unstructured":"Bonello L, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart. 2007;93:703\u20137.","journal-title":"Heart"},{"key":"724_CR156","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0167-5273(00)00443-5","volume":"77","author":"PG Steg","year":"2001","unstructured":"Steg PG, et al. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol. 2001;77:263\u201373.","journal-title":"Int J Cardiol"},{"key":"724_CR157","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1177\/000331979704800505","volume":"48","author":"A Birand","year":"1997","unstructured":"Birand A, Kudaiberdieva GZ, Batyraliev TA, Akgul F, Usal A. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology. 1997;48:413\u201322.","journal-title":"Angiology"},{"key":"724_CR158","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00392-013-0611-0","volume":"102","author":"JS Kim","year":"2013","unstructured":"Kim JS, et al. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry. Clin Res Cardiol. 2013;102:915\u201322.","journal-title":"Clin Res Cardiol"},{"key":"724_CR159","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s10557-022-07340-0","volume":"37","author":"NM El-Khodary","year":"2023","unstructured":"El-Khodary NM, Ghoneim AI, El-Tayaar AA, El-Touny EM. The impact of trimetazidine on cardiac fibrosis, inflammation, and function in ischemic cardiomyopathy patients. Cardiovasc Drugs Ther. 2023;37:955\u201364.","journal-title":"Cardiovasc Drugs Ther"},{"key":"724_CR160","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5582\/ddt.2022.01020","volume":"16","author":"RP Harjoko","year":"2022","unstructured":"Harjoko RP, et al. Trimetazidine improves left ventricular global longitudinal strain value in patients with heart failure with reduced ejection fraction due to ischemic heart disease. Drug Discov Ther. 2022;16:177\u201384.","journal-title":"Drug Discov Ther."},{"key":"724_CR161","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1007\/s12325-022-02315-x","volume":"39","author":"Z Min","year":"2022","unstructured":"Min Z, Xuelu L, Ran Z, Qiuhong S, Yong M. Effectiveness of trimetazidine in patients with chronic heart failure stratified by the expression of soluble suppression of tumorigenicity-2 (sST2): a prospective cohort study. Adv Ther. 2022;39:5514\u201329.","journal-title":"Adv Ther"},{"key":"724_CR162","doi-asserted-by":"publisher","first-page":"65","DOI":"10.18087\/cardio.2021.11.n1801","volume":"61","author":"MG Bubnova","year":"2021","unstructured":"Bubnova MG, Aronov DM. Efficacy of trimetazidine - an inhibitor of free fatty acids oxidation in the treatment of patients with stable angina pectoris and heart failure. Kardiologiia. 2021;61:65\u201376.","journal-title":"Kardiologiia"},{"key":"724_CR163","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","volume":"4","author":"CJ Coats","year":"2019","unstructured":"Coats CJ, et al. Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy. JAMA Cardiol. 2019;4:230\u20135.","journal-title":"JAMA Cardiol."},{"key":"724_CR164","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cardfail.2014.01.004","volume":"20","author":"JL Winter","year":"2014","unstructured":"Winter JL, et al. Effects of trimetazidine in nonischemic heart failure: a randomized study. J Card Fail. 2014;20:149\u201354.","journal-title":"J Card Fail"},{"key":"724_CR165","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.lfs.2012.03.015","volume":"92","author":"P Zhao","year":"2013","unstructured":"Zhao P, et al. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci. 2013;92:633\u20138.","journal-title":"Life Sci"},{"key":"724_CR166","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/hrt.2003.031310","volume":"91","author":"P Di Napoli","year":"2005","unstructured":"Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart. 2005;91:161\u20135.","journal-title":"Heart"},{"key":"724_CR167","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jacc.2006.03.060","volume":"48","author":"G Fragasso","year":"2006","unstructured":"Fragasso G, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006;48:992\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"724_CR168","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0267659120957856","volume":"36","author":"H Fu","year":"2021","unstructured":"Fu H, et al. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency. Perfusion. 2021;36:603\u20139.","journal-title":"Perfusion"},{"key":"724_CR169","first-page":"191","volume":"13","author":"A Mirhosseni","year":"2019","unstructured":"Mirhosseni A, et al. Preventive effect of trimetazidine on contrast-induced acute kidney injury in CKD patients based on urinary neutrophil gelatinase-associated lipocalin (uNGAL): a randomized Clinical Trial, Iran. J Kidney Dis. 2019;13:191\u20137.","journal-title":"J Kidney Dis"},{"key":"724_CR170","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.carrev.2017.02.006","volume":"18","author":"TA Ibrahim","year":"2017","unstructured":"Ibrahim TA, El-Mawardy RH, El-Serafy AS, El-Fekky EM. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. Cardiovasc Revasculariz Med. 2017;18:315\u20139.","journal-title":"Cardiovasc Revasculariz Med."},{"key":"724_CR171","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/MAJ.0000000000000575","volume":"350","author":"W Liu","year":"2015","unstructured":"Liu W, et al. Trimetazidine prevention of contrast-induced nephropathy in coronary angiography. Am J Med Sci. 2015;350:398\u2013402.","journal-title":"Am J Med Sci"},{"key":"724_CR172","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/hrt.2006.097477","volume":"93","author":"AO Onbasili","year":"2007","unstructured":"Onbasili AO, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart. 2007;93:698\u2013702.","journal-title":"Heart"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00724-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00724-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00724-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:03:09Z","timestamp":1751702589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00724-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":172,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00724-1","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"17 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Harsh Goel, MD; Nicholas Roma, MD; Michael Morgan, MD; Riya Arora; Nayanika Sreejith; Deepak Goyal; and Sunil Nadar, MD, have no potential conflicts of interest that might be relevant to the contents of this manuscript","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Harsh Goel, Deepak Goyal, Sunil Nadar: conceptualization, writing, and reviewing. Michael Morgan, Nicholas Roma, Nayanika Sreejith, Riya Arora: literature search, collating\/organizing literature search, organizing data in tables, reviewing, and editing.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated for this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}